Evoke Pharma, Inc. expected to return to positive sequential revenue growth in 2023 as the sales mix returns to levels saw in the first 3 quarters of 2022.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.461 USD | -2.95% | -5.05% | -56.11% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-56.11% | 3.91M | |
+30.38% | 684B | |
+26.51% | 568B | |
-4.36% | 361B | |
+19.30% | 329B | |
+3.73% | 284B | |
+16.70% | 240B | |
+8.78% | 208B | |
-7.93% | 200B | |
+7.68% | 166B |
- Stock Market
- Equities
- EVOK Stock
- News Evoke Pharma, Inc.
- Evoke Pharma, Inc. Provides Revenue Guidance for 2023